All In Biotech

Drug Trial Radar · NCT02207816

An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa

Extension to Study MALARIA-055 PRI (NCT00866619) for Evaluation of Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine (SB257049) in Infants and Children in Africa

Last checked: Nov 19, 2026Latest source record: Nov 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,084 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,084

Actual

Start

Sep 18, 2014

Primary completion

Jan 31, 2017

Study completion Jan 31, 2017

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 42 months, up to 9 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to conduct long-term surveillance for efficacy, safety and immunogenicity of the GSK Biologicals RTS,S/AS01E candidate Plasmodium falciparum malaria vaccine in infants and children in Africa following a primary vaccination series (NCT00866619). No new subjects will be enrolled in this extension study.

Conditions

  • Malaria

Interventions

  • Blood samplingProcedure

    Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.

  • Malaria Vaccine 257049 (MALARIA-055 PRI)Biological

    Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).

  • Meningococcal C Conjugate Vaccine (MALARIA-055 PRI)Biological

    Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).

  • Cell-culture rabies vaccine (MALARIA-055 PRI)Biological

    Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).

  • TritanrixHepB/Hib (MALARIA-055 PRI)Biological

    Administered intramuscularly into the left deltoid, during the MALARIA-055 study (NCT00866619).

  • Polio Sabin Oral Polio Vaccine (GSK) (MALARIA-055 PRI)Biological

    Administered orally, during the MALARIA-055 study (NCT00866619).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Severe Malaria Meeting Case Definition 1Time frame: From Year 0 to Year 3 (Starting January 2014 and ending December 2016)
  2. Incidence of Severe Malaria Meeting Case Definition 2.Time frame: From Year 0 to Year 3 (Starting January 2014 and ending December 2016)

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Ouagadougou, Burkina Faso

  • GSK Investigational Site

    Kisumu, Kenya

  • GSK Investigational Site

    Tanga, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.